Karyopharm Therapeutics Inc

3. aug 2026, 23:41 UTC

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

1. aug 2026, 00:01 UTC

Karyopharm Therapeutics Inc shares are higher in after-market hours, reaching their highest cumulative return of the day despite recent underperformance.

31. juuli 2026, 23:31 UTC

Karyopharm Therapeutics shares rose during after-market hours, continuing a recovery from an earlier low. The stock remains below its 20-day moving average.

30. juuli 2026, 23:41 UTC

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

29. juuli 2026, 19:27 UTC

Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.

27. juuli 2026, 19:07 UTC

Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.

24. juuli 2026, 19:42 UTC

Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.

23. juuli 2026, 09:01 UTC

Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.

22. juuli 2026, 18:41 UTC

Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.

21. juuli 2026, 20:12 UTC

Karyopharm Therapeutics shares are lower in after-market hours, with no specific news driving the decline despite positive sentiment in U.S. markets.

20. juuli 2026, 23:01 UTC

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.